Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis-1 with Everolimus: A Phase II, Open-Label, Single-Arm Trial.

导出 OA

翻译打印收藏纠错

作者： John M,Slopis ^[1] ; Octavio,Arevalo ^[2] ; Cynthia S,Bell ^[3] ; Adelaide A,Hebert ^[2] ; Hope,Northrup ^[2] ; Roy F,Riascos ^[4] ; Joshua A,Samuels ^[2] ; Keri C,Smith ^[3] ; Patti,Tate ^[2] ; Mary Kay,Koenig ^[5]

作者单位： Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ^[1] Department of Pediatrics, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA. ^[2] Department of Diagnostic and Interventional Imaging, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA. ^[3] Department of Dermatology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA. ^[4] Department of Pathology and Laboratory Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA. ^[5] Department of Pediatrics, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA. mary.k.koenig@uth.tmc.edu. ^[6] Department of Pediatrics, Division of Child and Adolescent Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, 6410 Fannin Street, UTPB 732, Houston, TX, 77030, USA. mary.k.koenig@uth.tmc.edu. ^[7]